Gilead Sciences
(NQ:
GILD
)
79.17
+0.45 (+0.57%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
27
28
29
30
31
32
33
34
Next >
2 High-Yielding Stocks You Can Buy and Hold for Years
October 23, 2021
They pay more than double what the average S&P 500 stock yields.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Can Merck's Antiviral for COVID Succeed Where Gilead's Failed?
October 23, 2021
Signs point to yes, but it's still early in the game.
Via
The Motley Fool
Exposures
COVID-19
Vaccine Makers Slump As Oral Antivirals Begin To Take Center Stage
October 18, 2021
Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost for the oral...
Via
Talk Markets
Crispr: A Fallen Angel In Gene Editing
October 16, 2021
As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it...
Via
Talk Markets
The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies
October 15, 2021
Companies working on sorely needed Covid treatments are innovating to keep up.
Via
Investor's Business Daily
This Company Revolutionizes What Matters for Hospitals, Big Pharma and Health Insurers
October 14, 2021
You can perch on a 1-legged stool and balance precariously on 2, but if you want to settle in with comfort and safety, you need 3 sturdy legs. With its secure, cloud-based...
Via
Benzinga
Will Crispr Stock — And Its Cancer Drug — Rise After Allogene's Massive Fall?
October 12, 2021
Crispr is planning to begin a registrational test in the first quarter of 2022.
Via
Investor's Business Daily
Molnupiravir? Not So Fast. What About Tollovir? — Here's Why You Should Know What That Means
October 12, 2021
Photo by Martin Sanchez on Unsplash Merck (NYSE: MRK) announced last Friday impressive results from its COVID-19 antiviral, molnupiravir. As vaccines are requiring a third booster...
Via
Benzinga
Exposures
COVID-19
Biotech Stocks Are Lagging, Is It Time to Rebalance Your Healthcare Portfolio?
October 11, 2021
You may have seen that biotech stocks have been in a funk. The IBB has broken through the SMA-200 support line near $160 and it holds a perilous perch at $155, up only about 2.5% year-to-date. The IBB...
Via
Talk Markets
Why Gilead Sciences Investors Shouldn't Give Up on Remdesivir Just Yet
October 06, 2021
A new study shows it is highly effective in preventing deaths if taken early.
Via
The Motley Fool
Topics
Death
Exposures
COVID-19
Death
NanoViricides Leaps Forward in its Quest to Defeat COVID-19
October 05, 2021
Photo by Louis Reed on Unsplash Since the coronavirus pandemic started, scientists have worked to develop a vaccine to inoculate the population and stop the spread of COVID-19....
Via
Benzinga
Exposures
COVID-19
Tesla and Merck Give Investors Some Hope
October 04, 2021
Friday’s rally appears to have lost its momentum over the weekend because stock futures are trading lower before Monday’s open. China’s troubled real estate...
Via
Benzinga
Galapagos Assumes Responsibility Of Late-Stage Filgotinib Trial In Crohn's Disease
October 04, 2021
Galapagos NV (NASDAQ: GLPG) has randomized the last patient into the DIVERSITY Phase 3 study of filgotinib in the induction and maintenance of remission in...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
October 01, 2021
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...
Via
Benzinga
Gilead's Kite Files US Application To Expand Use Of Yescarta In Second-Line Setting
October 01, 2021
Kite Pharma, a Gilead Science Inc Company (NASDAQ: GILD), has submitted a supplemental marketing application to the FDA for Yescarta (axicabtagene ciloleucel...
Via
Benzinga
Exposures
Product Safety
3 Top Dividend Stocks Yielding More Than 4%
September 30, 2021
Make the most of your money with these generous income stocks.
Via
The Motley Fool
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
October 01, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...
Via
Benzinga
Exposures
Product Safety
Merck's COVID-19 Antiviral Pill Effective Against Variants, Lab Studies Show
September 29, 2021
Merck & Co Inc (NYSE: MRK) presented a study at a medical conference early Wednesday for its experimental COVID-19 antiviral candidate. What Happened: Laboratory...
Via
Benzinga
Exposures
COVID-19
GSK, Pfizer Backed Long-Acting HIV Med Under FDA Priority Review As Preventative Option
September 28, 2021
The FDA has accepted and granted Priority Review to ViiV Healthcare's marketing application seeking approval for injectable cabotegravir long-acting for...
Via
Benzinga
Exposures
Product Safety
Gilead Scores Fifth Approval For Trodelvy In Triple-Negative Breast Cancer, This Time In Canada
September 28, 2021
Health Canada has approved Gilead Sciences Inc's (NASDAQ: GILD) Trodelvy (sacituzumab govitecan-hziy) for previously treated breast cancer patients. The approval...
Via
Benzinga
Pfizer Begins Late-Stage Study To Test Effectiveness Of Oral Drug Against COVID-19 In Those Exposed To The Virus
September 28, 2021
Pfizer Inc (NYSE: PFE) says it has begun late-stage testing for an oral drug that can be taken by persons who are exposed to the virus that causes COVID-19. What Happened: The New...
Via
Benzinga
Exposures
COVID-19
Acceleron Stock Heats Up On $11 Billion Takeover Rumor; So, Who's The Buyer?
September 27, 2021
A biotech working in lung and blood diseases, as well as cancer, could be acquired.
Via
Investor's Business Daily
Acceleron In Advanced $11B Buyout Talks: Bloomberg
September 27, 2021
Frothy rumors about possible M&A discussions at Acceleron Pharma Inc (NASDAQ: XLRN) were capped with a Bloomberg report asserting that the Company is...
Via
Benzinga
7 Members Of Congress Failed To Disclose Stock Transactions: Who Was Named, And What's Next?
September 24, 2021
The call for members of Congress to be banned from buying and selling stocks continues to heat up with a new report that seven members of the House of Representatives failed to...
Via
Benzinga
3 Relatively Safe Pharma Stocks You Can Buy Right Now
September 23, 2021
These stocks should be less volatile than many of the alternatives.
Via
The Motley Fool
EXCLUSIVE: NanoViricides' Remdesivir-Encapsulated COVID-19 Therapy Shows Encouraging Preclinical Safety Profile
September 21, 2021
NanoViricides Inc (NYSE: NNVC) has reported significant advantages gained by remdesivir encapsulation within its lead COVID-19 candidate, thus showing a potential pan-...
Via
Benzinga
Exposures
COVID-19
Barron's Latest Picks And Pans: Apple, Bitcoin, a Goldman Sachs ETF, Nike And More
September 18, 2021
This weekend's Barron's cover story examines the t...
Via
Benzinga
Baidu, Gilead Sciences And Nvidia Stocks Provide Plays For Both Bulls And Bears: Here's How
September 17, 2021
Baidu. Inc (NASDAQ:BIDU), Gilead Sciences, Inc
Via
Benzinga
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
September 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (...
Via
Benzinga
Look For The Q4 Biotech Bounce In Mid-Small Caps
September 17, 2021
Large-cap biopharma stocks are off their highs because of prospects that drug prices may be directly negotiated through Medicare but several Democrats are not in agreement as to how this could be best...
Via
Talk Markets
< Previous
1
2
...
27
28
29
30
31
32
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.